Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Boston Scientific is a global developer and manufacturer of medical devices for interventional specialties, including cardiology, endosurgery, and neuromodulation. The 2006 fiscal year was defined by the transformative acquisition of Guidant Corporation on April 21, 2006, for a total purchase price of $28.4 billion. This acquisition established Boston Scientific as a major provider in the Cardiac Rhythm Management (CRM) market and diversified its portfolio. The company operates through three primary business groups: Cardiovascular (80% of sales), Endosurgery (17%), and Neuromodulation (3%).
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Net Sales | $7,821 million | $6,283 million |
| Gross Profit | $5,614 million (71.8% margin) | $4,897 million (77.9% margin) |
| Operating Income (Loss) | $(2,949) million | $968 million |
| Net Income (Loss) | $(3,577) million | $628 million |
| Diluted EPS | $(2.81) | $0.75 |
| Operating Cash Flow | $1,845 million | $903 million |
| Total Debt | $8,902 million | $2,020 million |
| Cash & Equivalents | $1,668 million | $848 million |
| Working Capital | $2,271 million | $1,152 million |
Note: The 2006 net loss includes approximately $4.5 billion in after-tax charges primarily related to the Guidant acquisition, including $4.1 billion in purchased research and development expenses.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 24% to $7.8 billion, driven largely by the inclusion of Guidant sales ($1.5 billion). However, legacy U.S. TAXUS stent sales declined 11% due to market uncertainty regarding late stent thrombosis.
- Profitability Decline: Gross margin decreased 6.1 percentage points to 71.8%, impacted by purchase accounting adjustments (inventory step-up), quality initiative costs (Project Horizon), and a shift toward lower-margin CRM products.
- Debt Expansion: Total borrowings increased to $8.9 billion from $2.0 billion to finance the Guidant acquisition. Interest expense rose to $435 million from $90 million.
- Segment Performance: Cardiovascular sales grew 27% to $6.2 billion. Endosurgery sales grew 10% to $1.3 billion. Neuromodulation sales surged 58% to $234 million.
Guidance, Outlook, and Risks
Management Outlook:
- CRM Recovery: Management expects the CRM market to recover over several years. Q4 2006 showed a 10% sequential sales increase, signaling stabilization.
- Stent Market: U.S. drug-eluting stent sales are expected to be below 2006 levels in 2007 due to market conservatism regarding late stent thrombosis. International sales are expected to remain consistent.
- Cost Reduction: The company plans to reduce the CRM workforce by 500-600 employees in Q1 2007 to reallocate resources to R&D and sales.
- Product Launches: Key upcoming launches include the TAXUS Liberté stent in the U.S. (subject to approval) and the PROMUS everolimus-eluting stent in Europe and Inter-Continental markets.
Material Risks and Contingencies:
- FDA Warning Letters: The company received corporate warning letters regarding quality system deficiencies at three facilities and a Guidant CRM facility. Resolution is required before new Class III device approvals or export certificates can be granted.
- Legal Proceedings: Significant exposure exists from product liability claims (particularly related to Guidant's defibrillators and pacemakers), patent litigation (notably with Johnson & Johnson and Medtronic), and securities litigation. The company is substantially self-insured.
- Debt Covenants: The company must maintain specific debt-to-EBITDA and interest coverage ratios. While compliant at year-end, the negative credit outlook from Moody's and S&P poses a risk to future borrowing costs.
Investor Verification Checklist
- Quality System Remediation: Verify the timeline and cost for resolving FDA warning letters and the impact on new product launch schedules (specifically TAXUS Liberté).
- CRM Market Share: Monitor quarterly CRM sales data to confirm the anticipated recovery of market share following industry-wide field actions.
- Debt Servicing: Assess the ability to generate sufficient operating cash flow to service $8.9 billion in debt and meet covenant requirements, given the negative credit outlook.
- Stent Market Dynamics: Track U.S. drug-eluting stent penetration rates and the impact of late stent thrombosis concerns on procedural volumes.
- Legal Accruals: Review Note J for updates on the $485 million legal accrual and potential for additional charges related to Guidant product liability claims.